InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

VANCOUVER , May 15, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as an RD pipeline of medications targeting diseases with high unmet medical needs, today reported financial results for the three and nine months ended March 31, 2019 , which is the Company’s third quarter of fiscal year 2019 (“3Q19”).

Eric A. Adams , InMed’s President and Chief Executive Officer, commented, “The third quarter of fiscal year 2019 was all about execution:  the team is firing on all cylinders, RD milestones are being accomplished, and we remain enthusiastic about our scientific advancements.  Further, our financial position remains strong and we are confident that our existing cash runway positions us to complete our forthcoming significant milestones – specifically to

... read more at: